Analysts forecast that Biocept, Inc. (NASDAQ:BIOC) will announce $1.40 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Biocept’s earnings, with the lowest sales estimate coming in at $1.39 million and the highest estimate coming in at $1.40 million. Biocept posted sales of $1.05 million in the same quarter last year, which suggests a positive year over year growth rate of 33.3%. The firm is scheduled to announce its next earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Biocept will report full year sales of $1.40 million for the current fiscal year, with estimates ranging from $5.80 million to $6.60 million. For the next financial year, analysts expect that the business will report sales of $9.12 million per share, with estimates ranging from $7.00 million to $10.46 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Biocept.

Biocept (NASDAQ:BIOC) last issued its quarterly earnings data on Thursday, August 10th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.01. Biocept had a negative return on equity of 550.35% and a negative net margin of 359.48%. The company had revenue of $1.28 million during the quarter, compared to analyst estimates of $1.23 million.

Several equities research analysts recently issued reports on the stock. Westpark Capital reissued an “outperform” rating on shares of Biocept in a research report on Thursday, August 3rd. ValuEngine raised shares of Biocept from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 6th. Finally, Zacks Investment Research cut shares of Biocept from a “buy” rating to a “hold” rating in a research report on Thursday, June 1st. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $2.25.

TRADEMARK VIOLATION WARNING: “Analysts Anticipate Biocept, Inc. (BIOC) Will Announce Quarterly Sales of $1.40 Million” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/09/analysts-anticipate-biocept-inc-bioc-will-announce-quarterly-sales-of-1-40-million.html.

An institutional investor recently raised its position in Biocept stock. Vanguard Group Inc. raised its holdings in shares of Biocept, Inc. (NASDAQ:BIOC) by 9.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 764,351 shares of the medical research company’s stock after buying an additional 66,746 shares during the period. Vanguard Group Inc. owned about 2.87% of Biocept worth $1,048,000 at the end of the most recent reporting period. Institutional investors own 6.92% of the company’s stock.

Biocept (NASDAQ:BIOC) opened at 1.41 on Friday. The firm’s market capitalization is $42.66 million. The stock has a 50 day moving average of $1.29 and a 200 day moving average of $1.61. Biocept has a one year low of $0.74 and a one year high of $3.39.

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Get a free copy of the Zacks research report on Biocept (BIOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biocept (NASDAQ:BIOC)

Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.